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Abstract: BACKGROUND: Group 2 innate lymphoid cells (ILC2s) play critical roles in induction and
exacerbation of allergic airway inflammation. Thus, clarification of the mechanisms that underlie the
regulation of ILC2 activation has received significant attention. Although ILCs are divided into three
major subsets that mirror helper effector T-cell subsets, counterpart subsets of regulatory T (Treg)
cells have not been well characterized. OBJECTIVE: We sought to determine the factors that induce
regulatory ILCs (ILCregs). METHODS: IL-10+ ILCregs induced from ILC2s by retinoic acid (RA) were
analyzed using RNA-sequencing and flow cytometry. ILCregs were evaluated in human nasal tissues
from healthy individuals and patients with chronic rhinosinusitis with nasal polyp (CRSwNP), and in
lung tissues from house dust mite (HDM)- or saline-treated mice. RESULTS: RA induced IL-10 secretion
by human ILC2s, but not type-2 cytokines. IL-10+ ILCregs, converted from ILC2s by RA stimulation,
expressed a Treg-like signature with the expression of IL-10, CTLA-4 and CD25, with down regulated
effector type 2-related markers such as CRTH-2 and ST2, and suppressed activation of CD4+ T cells
and ILC2s. ILCregs were rarely detected in human nasal tissue from healthy individuals or lung tissues
from saline-treated mice, but were increased in nasal tissues from patients with CRSwNP and in lung
tissues from HDM-treated mice. Enzymes for RA synthesis were up-regulated in airway epithelial cells
during type-2 inflammation in vivo and by IL-13 in vitro. CONCLUSION: We have identified a unique
immune regulatory and anti-inflammatory pathway by which RA converts ILC2s to ILCregs. Interactions
between airway epithelial cells and ILC2s play an important roles in the generation of ILCregs.
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RALDH: Retinaldehyde dehydrogenase
 ILC2: Group 2 innate lymphoid cell
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Background: Group 2 innate lymphoid cells (ILC2s) play critical roles in induction and 73 
exacerbation of allergic airway inflammation. Thus, clarification of the mechanisms that 74 
underlie the regulation of ILC2 activation has received significant attention. Although 75 
ILCs are divided into three major subsets that mirror helper effector T-cell subsets, 76 
counterpart subsets of regulatory T (Treg) cells have not been well characterized.  77 
Objective: We sought to determine the factors that induce regulatory ILCs (ILCregs). 78 
Methods: IL-10+ ILCregs induced from ILC2s by retinoic acid (RA) were analyzed 79 
using RNA-sequencing and flow cytometry. ILCregs were evaluated in human nasal 80 
tissues from healthy individuals and patients with chronic rhinosinusitis with nasal polyp 81 
(CRSwNP), and in lung tissues from house dust mite (HDM)- or saline-treated mice. 82 
Results: RA induced IL-10 secretion by human ILC2s, but not type-2 cytokines. IL-10+ 83 
ILCregs, converted from ILC2s by RA stimulation, expressed a Treg-like signature with 84 
the expression of IL-10, CTLA-4 and CD25, with down regulated effector type 2-related 85 
markers such as CRTH-2 and ST2, and suppressed activation of CD4
+
 T cells and ILC2s. 86 
ILCregs were rarely detected in human nasal tissue from healthy individuals or lung 87 
tissues from saline-treated mice, but were increased in nasal tissues from patients with 88 
CRSwNP and in lung tissues from HDM-treated mice. Enzymes for RA synthesis were 89 
up-regulated in airway epithelial cells during type-2 inflammation in vivo and by IL-13 in 90 
vitro. 91 
Conclusion: We have identified a unique immune regulatory and anti-inflammatory 92 
pathway by which RA converts ILC2s to ILCregs. Interactions between airway epithelial 93 
cells and ILC2s play an important roles in the generation of ILCregs. 94 
Key messages: 95 





















ILCregs suppress activation of CD4
+
 T cells and ILC2s through IL-10 production. 97 
ILCregs are induced in the airways during type-2 airway inflammation by interacting 98 
with epithelial cells to avoid excessive tissue injury and inflammation. 99 
 100 
Capsule summary: 101 
This study shows a novel immune regulatory pathway that avoids excessive lung 102 
inflammation through conversion of ILC2s to ILCregs by retinoic acid that is synthesized 103 
by airway epithelial cells. 104 
 105 
 106 
Key words: Regulatory innate lymphoid cells, Group 2 innate lymphoid cells, retinoic 107 
acid, IL-33, asthma, chronic rhinosinusitis with nasal polyps, CTLA-4 (cytotoxic 108 
T-lymphocyte-associated protein 4) 109 
 110 
Abbreviation used: 111 
Air-liquid interface: ALI 112 
Bronchoalveolar lavage fluid: BALF 113 
Chemoattractant receptor-homologous molecule on Th2 cells: CRTh2 114 
Chemokine (C-C motif) ligand 5: CCL5 115 
Chronic rhinosinusitis with nasal polyps: CRSwNP 116 
Cytotoxic T-lymphocyte-associated protein 4: CTLA-4 117 
Genome-wide association study: GWAS 118 
Group 1 innate lymphoid cells: ILC1s 119 





















Group 3 innate lymphoid cells: ILC3s 121 
House dust mite: HDM 122 
IL-10 receptor: IL-10R 123 
Inducible costimulator: ICOS 124 
Inducible costimulator ligand: ICOSL 125 
Innate lymphoid cells: ILCs 126 
Interferon: IFN 127 
Peripheral Treg cells: pTreg cells 128 
Regulatory T: Treg 129 
Regulatory ILCs (ILCregs) 130 
Retinaldehyde dehydrogenase: RALDH 131 
Retinoic acid: RA 132 
Retinoic acid receptor: RAR 133 
Retinoic acid receptor inhibitor (RAi) 134 
RNA sequencing technologies: RNA-seq 135 
Thymus-derived Treg cells: tTreg cells 136 
Transforming growth factor-β: TGF-β 137 
  138 
Introduction 139 
Innate lymphoid cells (ILCs) are newly identified lymphoid lineage immune cells. They 140 
do not have rearranged antigen receptors; instead, they respond promptly to multiple 141 
cell-derived factors, such as cytokines and eicosanoids, which are released from infected 142 
or injured tissues. Like helper T cells, ILCs are currently divided into three distinct 143 





















group 1 ILCs (ILC1s) express T-bet and produce interferon (IFN)-γ to control 145 
intracellular pathogens such as viruses and intracellular bacteria. Group 2 ILCs (ILC2s) 146 
express GATA-3 and produce IL-5 and IL-13 to control helminths. Group 3 ILCs (ILC3s) 147 
express ROR-γt and produce IL-17A and IL-22 to control extracellular bacteria.1-3 Recent 148 
reports highlighted the importance of ILCs not only in early immune responses against 149 
pathogens, but also in induction and exacerbation of inflammatory diseases.
3-5
 ILC2s in 150 
particular are known to play crucial roles in allergic diseases such as asthma and chronic 151 
rhinosinusitis with nasal polyps (CRSwNP) through production of type-2 cytokines. For 152 
instance, a genome-wide association study (GWAS) demonstrated that strong 153 
associations between asthma development and genetic polymorphisms in the gene 154 
encoding IL-33, which is a major activator of ILC2s,
6
 and its receptor IL-1RL1 (ST2).
7
 In 155 
line with this, the frequency of ILC2s was significantly increased in bronchoalveolar 156 
lavage fluid (BALF) from patients with asthma compared to control subjects, and it 157 
correlated negatively with airway function,
3
 strongly indicating that ILC2s are involved 158 
in the pathogenesis of asthma. Numerous studies using various animal models of asthma 159 
also elucidated indispensable roles for IL-33 and ILC2s in allergic airway 160 
inflammation.
8-12
 Moreover, ILC2s were activated as well as increased in nasal tissues 161 
from patients with CRSwNP and they were associated with eosinophil infiltration,
13, 14
 162 
suggesting that they are involved in allergic diseases induced by type-2 immune 163 
responses.  164 
Therefore, regulatory factors that suppress ILC2 activation have received broad attention 165 
as new therapeutic targets for allergic diseases. Thus far, our group and others have 166 
shown that ILC2 activation was suppressed by regulatory T (Treg) cells through IL-10,
10, 167 
15





















ligand inducible costimulator ligand (ICOSL) interaction,
15
 as well as recombinant 169 
cytokines such as IL-10 and TGF-β.17 ILC2 activation was also suppressed by type 1 170 
cytokines such as IFN-β,18, 19 IFN-γ18−21 and IL-27,18, 19 and lipid mediators such as 171 
prostaglandin I2 
22
 and lipoxin A4.
23
  172 
 Very recently, Wang et al. demonstrated the existence of IL-10
+
 regulatory ILCs 173 
(ILCregs) in mouse and human intestines.
24
 They also reported that ILCregs suppressed 174 
activation of ILC1s and ILC3s through IL-10 production. However, the existence and 175 
roles of ILCregs in the airways remain unclear. In the present study, we demonstrated that 176 
a vitamin A metabolite, retinoic acid (RA), induces IL-10-producing ILCregs from ILC2s. 177 
In vitro, ILCregs induced from ILC2s, acquired a Treg-like signature, down regulate type 178 
2 and an effector lymphocyte signature, and suppressed T cell and ILC2 proliferation 179 
through IL-10 production. In addition, we found that ILCregs can be induced from ILC2s 180 
in airway tissues during type-2 inflammation in both humans and mice. During type-2 181 
airway inflammation, IL-13, a major type-2 cytokine produced by ILC2s and Th2 cells, 182 
induces RA synthesis in airway epithelial cells that may result in induction of ILCregs 183 
that control allergic airway inflammation.  184 
 185 
Methods 186 
The detailed methods, including experimental protocols and statistical analysis, are 187 
presented in the Methods section of this article’s Online Repository at 188 
www.jacionline.org. 189 
 190 





















Human peripheral blood mononuclear cells (PBMCs) of healthy donors were isolated by 192 






 cells by AutoMACS 193 










 cells were sorted with 194 











 cells were expanded in Yssel’s medium 196 
supplemented with 1% human AB serum, together with irradiated allogeneic PBMCs and 197 
100 U/ml recombinant human IL-2 (Proleukin, Novartis, Basel, Switzerland) for 3 198 
weeks. The typical fold-expansion after 3 weeks was 100 to 500. For human ILC2 clones, 199 










 cells with a FACS Aria II 200 
as above, the sorted cells were sorted again with FACS Aria II in a single cell mode into a 201 
96-well plates filled with Yssel’s medium supplemented with 1% human AB serum, 202 
together with irradiated allogeneic PBMCs and 100 U/ml recombinant human IL-2 for 203 
3-week culture.  204 
 205 
Flow cytometric analysis 206 
Cell-surface protein and intracellular cytokines and transcription factors were stained by 207 
specific antibodies. After staining, the cells were analyzed by ARIA II or LSR Fortessa 208 
(BD Bioscience). 209 
 210 
Quantitative real-time PCR 211 
Total RNA was extracted and purified using RNeasy Mini Kit and RNeasy Micro Kit 212 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Total RNA was 213 
reverse-transcribed into cDNA using a RevertAid RT kit containing random hexamers 214 





















mix (Thermo Fischer Scientific) on an ABI PRISM 7000 Sequence Detection System 216 
(Applied Biosystems, Foster City, CA). Sequences of the primers for detecting target 217 
gene expression are listed in Table E2. 218 
 219 
RNA isolation and sequencing analysis of RNA-seq data 220 

















 cells using the RNeasy Plus micro Kit (QIAGEN). Library 222 
preparation for RNA-seq was performed using the TruSeq Stranded mRNA Sample Prep 223 
Kit (Illumina, CA). Sequencing was performed on an Illumina HiSeq 2500, with 224 
paired-end 2x126 bp or single-end 126 bp, using a TruSeq SBS Kit v4-HS (Illumina). 225 
Differential expression analysis between two groups was performed using the edgeR 226 
Bioconductor package. 227 
 228 
Cell isolation from human tissues 229 
Nasal tissues were cut into fine pieces and digested for 45 min at 37°C in RPMI medium 230 
(Thermo Fisher Scientific) with 2mg/ml collagenase type II (Worthington, Lakewood, 231 
NJ) and 0.04 µg/ml DNase I (Roche, Basel, Switzerland). After incubation, cells were 232 
dissociated using GentleMACS Dissociator (Miltenyi Biotec). Lung mononuclear cells 233 
were isolated as previously described.
25
 In brief, lung tissues were minced and digested 234 
for 40 min at 37°C in RPMI medium (Thermo Fisher Scientific) with 0.25 mg/ml 235 
collagenase type II (Sigma-Aldrich) and 0.2 mg/ml DNase (Roche). After incubation, the 236 
tissues were mechanically disrupted using a 50-ml syringe and 100-µm filter. Cell debris 237 
and larger alveolar macrophages were separated by density centrifugation using 30% 238 






















C57BL/6J wild-type mice were purchased from Japan SLC, Inc. IL-10
Venus
 reporter mice 241 
were generated as described previously
26
. All mice were housed under 242 
specific-pathogen-free conditions in an environmentally-controlled clean room at the 243 
National Research Institute for Child Health and Development (Tokyo, Japan). All 244 
experiments were conducted in accordance with the institutional ethical guidelines for 245 
animal experiments and safety guidelines for gene manipulation. 246 
 247 
Statistical analysis 248 
Statistical analysis of RNA-seq data was performed as described above. Otherwise, all 249 
data were analyzed using an unpaired Student’s t-test and one-way ANOVA. All analyses 250 
were performed using GraphPad Prism (GraphPad Software, La Jolla, CA) 251 
 252 
Results 253 
Retinoic acid induces IL-10 production by human ILC2s 254 
Most Treg cells are differentiated in the thymus, and they are termed thymus-derived 255 





 T cells, and they are termed peripheral Treg cells (pTreg 257 
cells).
27
 These facts suggest that Treg cells can be generated in nonlymphoid tissues in 258 
response to environmental cues. ILCs are highly plastic,
13, 28-32
 thus enabling them to 259 
respond promptly to microenvironmental changes. In this context, we hypothesized that 260 
ILC2s change their phenotype to a regulatory phenotype in response to certain 261 
environmental cues. We first attempted to clarify if factors that contribute to 262 





















lines into a regulatory phenotype. Among those factors, we found that RA, but neither 264 
TGF-β nor vitamin D, induced IL-10 production, which was more pronounced in the 265 
presence of IL-33 (Fig 1, A). Next, we investigated whether RA also modulated 266 
production of other cytokines/chemokines by ILC2 lines. We observed that RA induced 267 
IL-10 production by ILC2 lines in a dose-dependent manner, but it did not enhance 268 
production of such type-2 cytokines as IL-5 and IL-13 (Fig 1, B). Conversely, RA 269 
suppressed production of an eosinophil-activating chemokine, i.e., chemokine (C-C 270 
motif) ligand 5 (CCL5), by ILC2 lines in a dose-dependent manner (Fig 1, B). Since RA 271 
was shown to act through its nuclear receptor, retinoic acid receptor (RAR),
36
 we 272 
included a pan-RAR inhibitor (RAi; BMS 493, Tocris Bioscience, Bristol, UK) to 273 
confirm whether these effects were induced through RAR. We found that RAi blocked 274 
the effects of RA on ILC2 lines in a dose-dependent manner (Fig 1, C). Taken together, 275 
these results demonstrate that RA induces IL-10 production and suppresses CCL5 276 
production by ILC2s through RAR.  277 
 278 
IL-10-producing ILCs acquire a Treg cell phenotype 279 
 To determine the characteristics of IL-10-producing ILCs induced from ILC2 lines by 280 




 ILCs using an IL-10 secretion assay after 281 
stimulation with IL-33 and RA (Fig E1, A). Then we performed transcriptome profiling 282 
of those cells by high-throughput RNA sequencing technologies (RNA-seq). Hierarchical 283 
clustering of the signal intensities of the individual transcripts in each group showed 284 
distinct transcript expression patterns for IL-10
+
 ILCs and IL-10
-
 ILCs (Fig E1, B). Of 285 
these, IL-10 was the most differentially expressed gene in IL-10
+
 ILCs, confirming the 286 





















ILC2s, such as chemoattractant receptor-homologous molecule on Th2 cells (CRTh2), 288 
CD127, OX40 ligand (OX40L) and c-Kit, were distinctly down-regulated in IL-10
+
 ILCs 289 
compared to IL-10
-
 ILCs (Fig 2, A, B and C) and ILC2 lines (Fig E1, C) at both the 290 
transcript and protein levels, suggesting that IL-10
+
 ILCs induced from ILC2 lines lost 291 
their ILC2 signature. However, the expression levels of cytokines and transcription 292 
factors for ILC2, such as IL-13 and GATA-3, were not changed in IL-10
+
 ILCs (Fig 2, C 293 
and Fig E1, C). In sharp contrast, genes encoding molecules that characterize Treg cells, 294 
such as CTLA-4 and CD25, were distinctly up-regulated in IL-10
+
 ILCs compared to in 295 
IL-10
-
 ILCs and ILC2 lines (Fig 2, A, D, E, and Fig E1, C), indicating that IL-10
+
 ILCs 296 
induced from ILC2s had acquired a Treg signature. Interestingly, cytokine and 297 
transcription factors such as TGF-β, Foxp3, Helios and Aiolos were not changed in 298 
IL-10
+
 ILCs at the protein level (Fig 2, E and Fig E1, C), whereas both IKZF2 and IKZF3, 299 
encoding Helios and Aiolos, were significantly upregulated at the transcript level. (Fig 2, 300 
A and D). Together these data suggest that IL-10
+
 ILCs lose the ILC2 phenotype, but 301 
acquire a Treg cell phenotype. 302 
 303 
ILCregs suppress the proliferation of CD4+T cells and ILC2s through IL-10 304 
production 305 
 To confirm the suppressive capacity of IL-10-producing ILCs induced from ILC2 lines 306 
by RA, we purified in vitro-induced IL-10+ ILCs and IL-10- ILCs using the IL-10 307 
secretion assay and then co-cultured them with autologous CD4
+
 T cells or ILC2 lines at 308 
different ratios. We found that IL-10
+
 ILCs suppressed the proliferation of CD4
+
 T cells 309 
induced by anti-CD3 stimulation in a dose-dependent manner (Fig 3, A), whereas IL-10
- 310 
ILCs did not (Fig E2, A). This suppressive effect of IL-10
+ 





















blocking the IL-10 receptor (IL-10R) (Fig 3, B), but not by blocking CTLA-4 (Fig 3, C), 312 
suggesting that IL-10
+
 ILCs suppress proliferation of CD4
+
 T cells through IL-10 313 
production. In addition, IL-10
+
 ILCs, but not IL-10
- 
ILCs, showed a dose-dependent 314 
suppression of ILC2-line proliferation induced by IL-2 (Fig 3, D and Fig E2, B), which 315 
was reversed by blocking IL-10R (Fig 3, E). To compare the suppressive capacity of 316 
IL-10
+ 






Treg cells from peripheral 317 
blood and co-cultured  them with autologous ILC2 lines at different ratios. We found that 318 
the suppressive effect of IL-10
+ 
ILCs on the proliferation of ILC2 lines was comparable 319 
to that of Treg cells (Fig 3, A and Fig E2, C). Taken together, these data clearly show that 320 
IL-10
+
 ILCs, differentiated from ILC2s, have suppressive function. 321 
 322 
Human ILC2 clones that are prone to be regulatory ILCs 323 
Next, we sought to determine the stability of IL-10
+ 





ILCs induced from human ILC2 lines, and then maintained them in a 325 
neutral condition, i.e., exposed only to IL-2, for 3 days to allow the cells to rest. 326 
Thereafter, half of the cells were stimulated with PMA, ionomycin and monensin, and 327 
then stained for IL-10. The other half of the cells were re-stimulated with IL-2, IL-33 and 328 
RA for 3 days, followed by PMA, ionomycin and monensin, and then stained for 329 
intracellular IL-10. We found that approximately 3.7 % of IL-10
+ 
ILCs were still able to 330 
produce IL-10 even after 3 days’ rest, whereas only a marginal proportion of IL-10
- 
ILCs 331 
were (Fig E3). In addition, approximately 23 % of IL-10
+ 
ILCs were able to produce 332 
IL-10 with RA stimulation after 3 days’ rest, whereas only a marginal proportion of 333 
IL-10
-
ILCs were (Fig E3). These findings suggest that IL-10
+
 ILCs retained the ability to 334 





















ILC2s that is capable of being converted to IL-10-producing cells. To confirm that, we 336 
generated ILC2 clones from peripheral blood of 5 healthy subjects. We isolated 35 clones 337 
and the efficiency of cloning ranged from 4% to 7%. Notably, none of these clones was 338 
positive for IL-10 without RA stimulation, but 28% of them (10 of 35 clones) became 339 
IL-10-positive when stimulated with RA plus IL-33 (Fig E4, A). In line with this, IL-10 340 
was detected in the culture supernatants of these 10 clones (Fig E4, B), whereas IL-10 341 
was not detected in the culture supernatant of any other clones. These findings confirmed 342 
that RA induced IL-10 production only in those 10 clones, but not in the remaining 25 343 
clones. To clarify the difference between the clones that remained IL-10 negative and 344 
those that started to produce IL-10 in response to RA stimulation, we determined their 345 
expression levels of such surface molecules as c-Kit, CD161 and CTLA-4, before RA 346 
stimulation. ILC2s in peripheral blood were shown to have 2 different subsets as a 347 
function of c-Kit expression
37
. However, there was no difference in c-Kit expression 348 
between the IL-10-secreting and non-secreting groups (Fig E4, C). Similarly, the 349 
expression levels of CD161 and CTLA-4 as well as cytokine productions (IL-5 and 350 
IL-13) were comparable within the two ILC groups (Fig E4, C and D).  351 








 cells, have been 352 
thought to be relatively homogeneous compared to ILC1s and ILC3s, our present results 353 
indicate that ILC2s are heterogeneous and comprise ILCreg precursors as a subgroup. 354 
 355 
ILCregs were induced in nasal tissues from patients with CRSwNP following ILC2 356 
interaction with epithelial cells 357 
 The finding of in vitro conversion of ILC2 to ILCregs raised the question of whether 358 





















disease states. To answer this question, we tested nasal tissues from healthy individuals 360 
and patients with CRSwNP. We found that ILCregs expressing IL-10 (median number: 9; 361 
range: 0-17) or CTLA-4 (median number: 2;, range 5-122) were present in nasal tissues 362 
from patients with CRSwNP (Fig 4, A, B and C). Interestingly ILCregs were rarely 363 
detected in nasal tissues from healthy subjects (Fig 4, A and B). These results show that 364 
the number of ILCregs is significantly upregulated in inflamed tissues, but not in 365 
non-inflamed tissues, suggesting that conversion to a regulatory phenotype occurs 366 
especially during inflammatory responses. Given that ILCregs were converted from 367 
ILC2s by RA stimulation in vitro, RA might be induced at local tissue sites during 368 
inflammation. To clarify whether RA is induced during inflammation, we determined the 369 
mRNA expression for ALDH1A1, ALDH1A2 and ALDH1A3, genes encoding for 370 
retinaldehyde dehydrogenase (RALDH)1, RALDH2 and RALDH3, respectively, in nasal 371 
tissues from the healthy subjects and patients with CRSwNP. RALDHs convert retinal to 372 
RA and are responsible for high RA concentrations in the tissues. We found that the 373 
expression of ALDH1A1 was significantly increased in nasal tissues from patients with 374 
CRSwNP compared to the healthy individuals (Fig 4, D). In contrast, the expression of 375 
ALDH1A2 was significantly decreased in nasal tissues from patients with CRSwNP 376 
compared to the healthy individuals, but the expression levels of ALDH1A2 were 377 
approximately 10-fold less than those of ALDH1A1 (Fig 4, D). Moreover, the expression 378 
of RALDH1 protein was increased in nasal epithelial cells from patients with CRSwNP 379 
compared to the healthy individuals (Fig 4, E), indicating that epithelial cells synthesize 380 
RA during inflammation. Interestingly, although there is a limitation regarding 381 
appropriate lineage markers for exclusion of other immune cell subsets, ILCregs were 382 





















4, C). In addition, we previously showed possible interaction between ILC2 and 384 
bronchial epithelial cells,
38
 raising the possibility that interaction between epithelial cells 385 
and ILC2s may be important for the conversion of ILC2s into ILCregs. To clarify the 386 
factors that promote synthesis of RA in airway epithelial cells, we stimulated air-liquid 387 
interface (ALI) cultures of primary bronchial epithelial cells from healthy individuals 388 
with IL-5, IL-13 and IL-33. We found that IL-13, but not IL-5 or IL-33, induced 389 
expression of ALDH1A1 and ALDH1A3 in ALI cultures of primary bronchial epithelial 390 
cells (Fig 4, F). These findings suggest that IL-13, a major type-2 cytokine produced 391 
mainly by ILC2s and Th2 cells, promoted RA synthesis to induce ILCregs, while 392 
inducing allergic airway inflammation. We also investigated human lung tissues to 393 
clarify the existence of ILCregs. As in the nasal tissues, ILCregs were rarely detected in 394 
mononuclear cells from non-inflamed lung tissues. However, the frequency of IL-10
+
 395 
ILCs was increased when those cells were stimulated with RA. (Fig 4, G).  396 
 Taken together, ILCregs are increased in the inflamed human airway, but are rare in the 397 
non-inflamed human airway, and interaction between ILC2s and bronchial epithelial 398 
cells at local sites of inflammation may be involved in induction of ILCregs. 399 
 400 
ILCregs were induced in the lungs, but not in the mesentery, of intranasally 401 
HDM-treated mice 402 
The findings in human nasal tissues indicated that ILCregs do not exist in the airways in a 403 
steady state, but are further induced during type-2 inflammation. To further evaluate 404 
these findings, we induced allergic airway inflammation by intranasal administration of 405 
an HDM extract to IL-10-reporter mice
26
. As previously reported,
39, 40
 ILC2s as well as 406 



























 cells were 408 
detected in BALFs and lungs from HDM-treated mice, but were rarely detected in those 409 






 cells in BALFs did not 410 
express CD4, but expressed such canonical markers as CD127 and CD90 (Fig 5, C), 411 






ILCs also expressed Sca-1 and 412 
KLRG1, which are lung ILC2 markers
41
 (Fig 5, C and E). To compare these cells with 413 
ILCregs recently found in the intestine, we determined the expression of a unique 414 
transcription factor of ILCregs found in the intestine, i.e., inhibitor of DNA binding 3 415 
(Id3), as well as key ILC2s markers such as GATA-3 and ST2. We found that IL-10
+ 416 
ILCs in the lung did not express Id3, whereas they expressed GATA-3 and ST2 (Fig 5, D), 417 
indicating that IL-10
+ 
ILCs in the lungs are distinct from ILCregs in the intestine and may 418 
be induced from ILC2s.  We also determined the frequency of ILCs in the mesentery, 419 
which is the site where ILC2s were originally found.
42
 We found that the frequency of 420 










 cells in the mesentery was increased 421 







ILCs were not detected in the mesentery from either saline-treated or 423 
HDM-treated mice (Fig 5, F), indicating that ILCregs are induced at local sites of 424 
inflammation only in response to environmental cues.  425 
To clarify whether RA is induced in the lung during inflammation, we determined the 426 
expression of RALDH-1 protein in lungs from HDM-treated and saline-treated mice. As 427 
seen in the nasal tissues from patients with CRSwNP, expression of RALDH-1 protein 428 
was markedly increased in the bronchial epithelial cells from HDM-treated mice 429 





















In summary, as seen in the human nasal tissues, ILCregs are present only in inflamed 431 
lungs and RA production by epithelial cells may play important roles. 432 
 433 
Discussion 434 
This study is the first to show that human ILCregs can be generated from ILC2s by RA 435 
and are present in the sinus tissues of patients with CRSwNP, but are rare in non-inflamed 436 
sinus tissues. Since ILCs have been considered to be tissue resident cells, with minimal 437 
hematogenous recruitment,
18, 43
 it was hypothesized that ILCregs can be induced from 438 
effector ILC subsets at local sites of inflammation. Indeed, ILCs are recognized as being 439 
highly plastic cells that can convert their phenotype according to environmental cues, 440 
enabling them to respond promptly to local microenvironmental changes. For instance, 441 
trans-differentiation between ILC1s and ILC3s in the intestinal lamina propria,
28, 29
 and 442 
between ILC1s and ILC2s in the lung
13, 31, 32
 has been reported. In vitro, ILC3s 443 
differentiated into ILC1s in response to IL-12, while ILC1s differentiated into ILC3s in 444 
response to IL-1β, IL-23 and RA.28, 29 Similarly, ILC2s differentiated into ILC1s in 445 
response to IL-1β and IL-12, while ILC1s differentiated into ILC2s in response to IL-4.13, 446 
30-32
 447 
 Vitamin A, which is normally obtained through consumption of certain foods, is needed 448 
for a variety of biological functions, including vision, embryonic development, brain 449 
function and immunity.
44
 Of these, vitamin A, through its metabolite RA, has garnered 450 
attention for its roles in immune regulation especially of T cells.
44
 For instance, RA was 451 
shown to be responsible for differentiation of naïve T cells to Treg cells
34, 45
 and to also 452 
contributes to the stability and function of Treg cells.
46
 Those findings suggest that RA 453 





















receptor gamma, was shown to be expressed in all subsets of human ILCs,
37
 suggesting 455 
that all ILC subsets can be potentially regulated by RA to some extent. Indeed, RA 456 
induced expression of gut-homing receptors such as CCR9 and α4β7 on ILC1s and 457 
ILC3s that result in migration of those cells to the intestine.
47
 RA, in combination with 458 
IL-1β and IL-23, also induced development of ILC3s and enhanced their production of 459 
IL-22 in mice.
48-51
 In contrast to its positive effects on development and function of 460 
ILC3s, RA was reported to inhibit development of ILC2s from ILC2 progenitors in 461 
mouse bone marrow.
49
 However, the effects of RA on proliferation and cytokine 462 
production of mature type-2 immune cells are controversial. Spencer et al. showed that 463 
RA suppressed proliferation and cytokine production of mouse ILC2s from the small 464 
intestinal lamina propria. RA also suppressed IL-7- and SCF-induced IL-13 production 465 








 In contrast, Trabanelli et al. showed 466 
that RA did not alter IL-13 production by human ILC2 lines stimulated with IL-2, IL-33 467 
or prostaglandin D2.
52
 In agreement with our data, Seehus et al. recently showed that RA 468 
induced production of IL-10, but not IL-13 by mouse ILC2s from the lung in response to 469 
stimulation with IL-2, IL-7 and IL-33.
53
 In addition, proliferation and type-2 cytokine 470 
production of human Th2 cells were shown to be enhanced by RA treatment.
54, 55
 This 471 
variation may be due to differences in the cell types and stimuli used in each study. RA is 472 
synthesized by one of three retinaldehyde dehydrogenases, RALDH1, RALDH2 and 473 
RALDH3,
44
 whose in vivo expression are strictly regulated both temporally and spatially, 474 
indicating that expression of RALDHs ensures the ability of each specific cell type to 475 
synthesize RA. In the present study, expression of RALDH1 was increased in nasal 476 
epithelial cells from patients with CRSwNP (Fig 4, E) and in bronchial epithelial cells 477 





















only in inflamed airway tissues during type-2 airway inflammation. Supporting that 479 
concept, ILCregs could not be detected in the mesentery from either saline-treated or 480 
HDM-treated mice (Fig 5, F). Others showed that expression of RALDH-1 was increased 481 
in bronchial epithelial cells in Aspergillus-induced allergic airway inflammation, and its 482 
expression was enhanced in matrix metalloproteinase 7 (MMP-7)-deficient mice 483 
compared to wild-type mice,
56
 suggesting that MMP-7 may be involved in regulation of 484 
RALDH-1 expression in bronchial epithelial cells. However, it is unclear how the 485 
absence of MMP-7 contributed to higher expression of RALDH-1 in those cells. In our 486 
study, RALDH1 expression was significantly increased in ALI-cultured primary 487 
bronchial epithelial cells by IL-13 stimulation (Fig 4, F). In addition, while there was only 488 
limited RALDH-1 expression in the airways of naïve and saline-treated mice, as 489 
previously reported,
56
 RALDH-1 expression was increased after induction of allergic 490 
airway inflammation (Fig 5, G). These findings indicate that IL-13-a major type-2 491 
effector cytokine produced mainly by ILC2s and Th2 cells during allergic airway 492 
inflammation-promotes RA synthesis in bronchial epithelial cells, which in turn may 493 
contribute to resolution of allergic airway inflammation. These mechanisms may 494 
comprise a negative feedback system for maintaining airway homeostasis.  495 
Since there is substantial heterogeneity in ILCs, recent studies attempted to determine the 496 
phenotypes and roles of ILCs in human tissues by analyzing single cells using single-cell 497 
RNA sequencing and mass cytometry.
37, 57, 58
 However, none of those studies detected the 498 
IL-10
+
 regulatory subset in human tissues. Recently, Wang et al. demonstrated the 499 
presence of IL-10
+
 ILCregs in intestinal specimens from both humans and mice in steady 500 
state.
24
 In addition, IL-10
+
 ILCregs were induced in the intestine during intestinal 501 





















intestinal ILCregs did not express Foxp3, suggesting that they are distinct from Treg cells. 503 
ILCregs in the intestine expressed ILC markers such as CD127 and Sca-1, but lacked 504 
ILC1 markers (i.e., NK1.1 and NKp46), ILC2 markers (i.e., ST2 and KLRG1) and ILC3 505 
markers (i.e., NKp46 and RORγt). In addition, ILCregs in the intestine were derived from 506 
α4β7+Id2high CHILP (common helper-like innate lymphoid cells precursors), but not their 507 
downstream precursor PLZF
+
 ILCP (common ILC precursors), and required d3 for 508 
development, which is unlike other ILC subsets, suggesting that ILCregs in the intestine 509 
are distinct from the other effector ILC subsets.
24
 In contrast to ILCregs in the intestine, 510 
IL-10
+
 ILCregs in the airways were rarely detected in the steady state, but were induced 511 
during type-2 inflammation, in both humans and mice (Fig 4, B and Fig 5, B). That 512 
suggests that ILCregs in the airways might have been converted from other effector ILC 513 
subsets at local sites of inflammation or migrated to the lungs from other organs such as 514 
the intestine. However, unlike ILCregs in the intestine, ILCregs in lungs from 515 
HDM-treated mice expressed KLRG1, GATA-3 and ST2, which are common markers of 516 
ILC2s, but did not express Id3 (Fig 5, C and D). In addition, Id3 was not differentially 517 
expressed on in vitro-induced human IL-10+ ILCregs compared to IL-10- ILCs (Fig E1, 518 
D). These findings indicate that IL-10
+
 ILCregs in the lungs and in vitro-induced human 519 
IL-10
+ 
ILCregs may be distinct from ILCregs in the intestine.  520 
Recently, Seehus et al. showed IL-10 producing ILCs, named ILC210, in lungs from 521 
IL-33-injected mice.
53
 In contrast to the human ILCregs shown in the present study, the 522 
gene encoding CTLA-4 was not differentially expressed in those ILC210 found in the 523 
lungs from IL-33-injected mice. In addition, transcription factors such as Atf3 and Foxf1, 524 
previously shown to be highly expressed on ILC210, were not differentially expressed on 525 





















like other subsets of ILCs and Tregs, ILCregs have different phenotypes and roles 527 
depending on the type of tissue, inflammation and animal model. Further studies, 528 
including single-cell analysis of ILCregs from different types of tissues, are needed to 529 
better understand the ILCreg subset. Regarding the stability of ILCregs, since human 530 
IL-10-producing ILCregs induced from ILC2s retained their ability to produce IL-10 in 531 
response to RA, but not without RA, after 3 days’ rest (Fig E3), RA could be of critical 532 
importance in maintaining ILCregs’ expression of IL-10. Interestingly, IL-10 533 
non-producing ILCs did not produce IL-10 even if the cells were re-stimulated with RA 534 
after 3 days’ rest (Fig E3), indicating that there may be a subpopulation of ILC2s that is 535 
capable of being converted to IL-10
+
 ILCregs. In the HDM-induced asthma-like model, 536 
IL-10
+ 
Tregs as well as IL10
+ 
ILCregs, but less IL-10
+ 
Bregs, were increased in lungs 537 
from HDM-treated mice (Fig E5, A and B). It is assumed that ILCregs may have 538 
suppressive capacity in vivo and have different roles compared to Treg and Breg cells in 539 
terms of antigen specificity. However, further studies are needed to clarify the 540 
suppressive capacity of ILCregs in vivo and their specific roles during active 541 
inflammation.  542 
In conclusion, the current study identifies a unique anti-inflammatory pathway by which 543 
ILC2s are converted to ILCregs by RA. In vitro, ILCregs can suppress the proliferation of 544 
CD4
+
 T cells and ILC2s through IL-10 production. ILCregs were induced in the airways 545 
during type-2 airway inflammation by interaction of ILC2s with airway epithelial cells at 546 
local sites of inflammation, which may contribute to resolution of the allergic airway 547 
inflammation. These mechanisms may represent a negative feedback system for 548 
maintaining and reestablishing airway homeostasis and avoiding excessive tissue injury 549 
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FIG 1. Retinoic acid induces IL-10, but not IL-5 or IL-13, in ILC2s through retinoic 574 
acid receptor. 575 
A, IL-10 production by human ILC2 lines exposed for 3 days to various types of stimuli 576 
in the presence of IL-2 (100 U/ml) and/or IL-33 (50 ng/ml). B, Production of cytokines by 577 
human ILC2 lines stimulated for 3 days with IL-2 and IL-33 in the presence of different 578 
doses of RA. C, Production of cytokines by human ILC2 lines stimulated for 3days with 579 
IL-2, IL-33 and RA (100nM), in combination with pan-retinoic acid receptor inhibitor 580 
(RAi; BMS 493, Tocris Bioscience, Bristol, UK). Data are shown as the mean ± SEM. n = 581 
5 per group in triplicate. *P<0.05, **P<0.01 between indicated groups. 582 
 583 
FIG 2. IL-10 producing ILC2s acquire a regulatory phenotype.  584 
A, Gene expression profiling of IL-10+ ILCs and IL-10- ILCs induced from ILC2 lines by 585 
IL-2, IL-33 and RA. Differentially regulated genes related to ILC2s and Treg cells were 586 
selected for heatmap analysis. B, Reduced ILC2-related mRNAs in IL-10+ ILCs induced 587 





 ILCs induced from ILC2s. D, Increased quantitative mRNAs of Treg 589 
cell-related molecules in IL-10
+
 ILCs compared to IL-10
-
 counterparts. E, Increased 590 
expression of Treg cell-related molecules, i.e., CTLA-4 and CD25, on IL-10
+
 ILCs by 591 
flow cytometry. 592 
 593 
FIG 3. IL-10-producing ILCs suppress proliferation of CD4+ T cells and ILC2s 594 
through IL-10. 595 
A, Decreased division of carboxyfluorescein succinimidyl ester (CFSE)-labeled CD4+ T 596 
cells in the presence of IL-10
+























 T cells with IL-10
+
 ILCs at a 2:1 ratio with anti-IL-10R blocking 598 
mAbs (5 µg/ml), anti-CTLA-4 blocking mAbs (5 µg/ml) or isotype control mAbs (5 599 
µg/ml). IL-10 (10 ng/ml) was used as a control. D, Co-culture of CFSE-labeled ILC2 600 
lines with IL-10
+
 ILCs at different ratios (indicated in the figure). E, Co-culture of 601 
CFSE-labeled ILC2 lines with IL-10
+
 ILCs at a 2:1 ratio with anti-IL-10R blocking Abs 602 
(5 µg/ml) or isotype control Abs (5 µg/ml). IL-10 (10 ng/ml) was used as a control. Cells 603 
were harvested after 3 days. The CFSE fluorescence level was analyzed by flow 604 
cytometry, and the division index was calculated. Data are shown as the mean ± SEM. n = 605 
3 per group in duplicate. *P<0.05, **P<0.01, ***P<0.001 between indicated groups.  606 
 607 
FIG 4. ILCs in nasal tissues from patients with CRSwNP exhibit a regulatory 608 
phenotype. 609 






















 cells in nasal tissue from healthy individuals (n = 7) 612 
and patients with CRSwNP (n = 7). Each dot represents a single donor. C, 613 









 ILCs by staining for CD3 and NCR1 (white), CD161 (red), 615 
IL-10 (green) and DAPI (blue). D, Expression of ALDH1A1, ALDH1A2 and ALDH1A3 616 
mRNA in nasal tissues from healthy individuals (n = 12) and patients with CRSwNP (n = 617 
7). E, Immunofluorescence staining of nasal tissues from healthy individuals and patients 618 
with CRSwNP, showing the expression of RALDH-1 by staining for RALDH-1 (red) and 619 
DAPI (blue). F, Expression of ALDH1A1, ALDH1A2 and ALDH1A3 mRNA in air-liquid 620 





















= 4) stimulated with various cytokines such as IL-5, IL-13 and IL-33 for 24 h. N.D.: not 622 
detected. G, Frequency of CD45+Lin-CD161+IL-10+ in lung mononuclear cells before 623 
and after 72 h stimulation with IL-2, IL-33 and RA (n = 5). Each dot represents a single 624 
donor. Data are shown as mean ± SEM. *P<0.05, ***P<0.001 between indicated groups.  625 
 626 
FIG 5. IL-10 producing ILCs were increased in inflamed lung tissue, but not in 627 
mesentery, in an HDM-induced asthma-like model. 628 







 cells in BALF and lungs tissues from mice 72 h after last 630 
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 cells in lungs tissues, assessed 632 

















 cells in lungs tissues. E, 634 
Immunofluorescence staining of lung tissue from IL-10 reporter mice after HDM 635 
inhalation, showing IL-10
+
 ILCs by staining for CD3 (purple), sca-1 (red), IL-10 (green) 636 







 cells in the mesentery from mice 72 h after the last intranasal 638 
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 8). G, Immunohistochemistry of RALDH-1 in 639 
lung tissues from wild-type mice 72 h after the last intranasal inhalation. Scale bars, 640 
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Supplementary Table E1 Top 50 upregulated genes in IL-10+ ILCs compared to 
IL-10- ILCs 
 
 Gene ID Gene Name Description Log2 Ratio p-Value 
1 ENSG00000136634 IL10 interleukin 10  7.018 1.12E-314 




vitellogenic-like  2.563 5.58E-07 
4 
ENSG00000186919 ZACN 
zinc activated ligand-gated 
ion channel  2.489 2.02E-07 
5 
ENSG00000159307 SCUBE1 
signal peptide, CUB 




with thrombospondin type 
1 motif, 10  2.116 0.0006577 
7 ENSG00000137558 PI15 peptidase inhibitor 15  2.076 4.90E-06 
8 
ENSG00000167037 SGSM1 
small G protein signaling 




kinase 1  2.061 0.001257 
10 
ENSG00000139174 PRICKLE1 
prickle homolog 1 
(Drosophila)  2.046 0.001768 




protein 3  1.93 1.72E-09 
13 
ENSG00000196208 GREB1 
growth regulation by 
estrogen in breast cancer 1  1.867 0.0003084 
14 ENSG00000100600 LGMN legumain  1.783 4.29E-15 
15 
ENSG00000102048 ASB9 
ankyrin repeat and SOCS 
box containing 9  1.762 2.02E-10 
16 ENSG00000069535 MAOB monoamine oxidase B  1.697 4.47E-12 





















18 ENSG00000006468 ETV1 ets variant 1  1.578 0.001964 
19 ENSG00000123689 G0S2 G0/G1switch 2  1.502 7.54E-09 




factor 5-like  1.444 0.001307 
22 ENSG00000171246 NPTX1 neuronal pentraxin I  1.428 4.01E-05 
23 
ENSG00000183508 FAM46C 
family with sequence 
similarity 46, member C  1.424 3.38E-21 
24 ENSG00000145839 IL9 interleukin 9  1.392 1.52E-16 
25 
ENSG00000176595 KBTBD11 
kelch repeat and BTB 
(POZ) domain containing 
11  1.381 9.63E-16 
26 ENSG00000125266 EFNB2 ephrin-B2  1.369 0.001467 
27 
ENSG00000162367 TAL1 
T-cell acute lymphocytic 




domain containing receptor 
2  1.33 0.0008892 




protein 2  1.308 5.15E-07 
31 
ENSG00000006075 CCL3 
chemokine (C-C motif) 
ligand 3  1.262 0.0002122 




protein-like 10  1.239 2.23E-06 
34 ENSG00000174804 FZD4 frizzled family receptor 4  1.237 0.0001337 
35 
ENSG00000178184 PARD6G 
par-6 family cell polarity 
























member 1  
37 
ENSG00000197992 CLEC9A 
C-type lectin domain 
family 9, member A  1.19 0.0009048 
38 
ENSG00000121807 CCR2 
chemokine (C-C motif) 
receptor 2  1.182 8.19E-16 
39 
ENSG00000173585 CCR9 
chemokine (C-C motif) 
receptor 9  1.169 6.38E-06 
40 
ENSG00000111052 LIN7A 
lin-7 homolog A (C. 
elegans)  1.161 1.93E-05 
41 
ENSG00000205683 DPF3 
D4, zinc and double PHD 
fingers, family 3  1.159 0.0009757 
42 
ENSG00000183625 CCR3 
chemokine (C-C motif) 
receptor 3  1.157 0.0001433 
43 
ENSG00000172243 CLEC7A 
C-type lectin domain 
family 7, member A  1.147 0.0001114 
44 ENSG00000099250 NRP1 neuropilin 1  1.129 4.68E-06 
45 
ENSG00000114541 FRMD4B 
FERM domain containing 
4B  1.124 7.67E-16 
46 
ENSG00000066468 FGFR2 
fibroblast growth factor 
receptor 2  1.123 0.0002789 
47 ENSG00000120075 HOXB5 homeobox B5  1.092 0.0001196 
48 
ENSG00000139988 RDH12 
retinol dehydrogenase 12 





protein 4  1.055 7.03E-25 





















Supplementary table E2. Sequences of primers designed in house. 
Gene Forward (5’-3’) Reverse (5’-3’) 
EF1a CTG AAC CAT CCA GGC CAA AT GCC GTG TGG CAA TCC AAT 
ALDH1A1 CTG CCG GGA AAA GCA ATC AAA TTC AAC AGC ATT GTC CAA GTC 
ALDH1A2 AGG GCA GTT CTT GCA ACC AT GCG TAA TAT CGA AAG GTT TTG ATG A 
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Morita H et al. Fig E3







































































































































Morita H et al. Fig E4


































































































































































































































































































































































Online methods 1 
 2 
Flow cytometry analysis 3 
The following antibodies against human proteins were used for flow cytometry analysis. 4 
Fluorescein isothiocyanate (FITC)-conjugated lineage markers: anti-CD1a (HI149), 5 
anti-CD3 (OKT3), anti-CD11c (3.9), anti-CD14 (HCD14), anti-CD16 (3G8), anti-CD19 6 
(HIB19), anti-CD34 (581), anti-CD94 (DX22), anti-CD123 (6H6), anti-CD303 (201A), 7 
anti-TCRαβ (IP26), anti-TCRγδ (B1), anti-FcεR1α (AER-37), APC-conjugated 8 
anti-CLTA-4 (L3D10), PE/Dazzle 594 anti-Foxp3 (206D), PE-Cy7-conjugated anti-CD127 9 
(A019D5), anti-IL-10 (JES3-9D7), anti-Helios (22F6), PerCP/Cy5.5-conjugated anti-CD25 10 
(BC96), anti-GATA3 (16E10A23), anti-CD161 (HP-3G10), Brilliant Violet 421-conjugated 11 
anti-CD117 (104D2), anti-LAP (TW4-2F8) and Brilliant Violet 510-conjugated anti-CD45 12 
(HI30) (all from BioLegend, San Diego, CA  phycoerythrin (PE)-conjugated 13 
anti-OX40L (ik-1), Alexa Flour 647-conjugated anti-CD294 (BM16), Brilliant violet 14 
421-conjugated anti-IL-13 (JES10-5A2) and anti-Aiolos (S50-895) (all from BD 15 
Biosciences). The following antibodies to mouse proteins were used for flow cytometry 16 
analysis. Purified anti-	
  PE-conjugated lineage markers: anti-CD3e 17 
(145-2C11), anti-CD4 (GK1.5), anti-CD8 (53-6.7), anti-CD19 (1D3), anti-B220 (16A), 18 
anti-CD49b (DX5) and anti-γδTCR (GL3) (all from BD Biosciences) anti-CD11b (M1/70), 19 
anti-CD11c (HL3) and anti-Gr1 (RB6-8C5) (all from BioLegend  anti-FceR1a 20 
(MAR-1) (Thermo Fisher Scientific, Waltham, MA), PE/Cy7-conjugated anti-CD127 21 





















anti-KLRG1 (2F1/KLRG1) (all from BioLegend). For intracellular cytokine staining, the 23 
cells were stimulated for 5 hours with 25 ng/ml PMA (Sigma-Aldrich) plus 1 µg/ml 24 
Ionomycin (Sigma-Aldrich) in the presence of 10 µg/ml Brefeldin A (Sigma-Aldrich) for the 25 
final 3 hours of culture, and subsequently fixed and stained using a Cytofix/Cytoperm kit Kit 26 
(BD biosciences). For staining of transcription factors, the Foxp3 Fix/Perm Buffer set 27 
(BioLegend) was used.   28 
 29 
IL-10 secretion assay 30 
Live IL-10
+
 ILCs and IL-10
-
 ILCs were isolated using an IL-10 secretion assay (Miltenyi 31 
Biotec) and a cell sorter, ARIA II (BD Biosciences). In brief, the ILC2s were stimulated with 32 
IL-2, IL-33 and RA. After 2 days’ culture at 37°C, cells were restimulated with IL-2, IL-33 33 
and RA and cultured for another 8 h. The cells were then harvested and labeled with Catch 34 
Reagent for 5 min at a concentration of 10
8
 cells/ml in ice-cold Yssel’s medium 35 
supplemented with 1% human AB serum. The cells were diluted in warmed-up medium to a 36 
final concentration of 10
6
 cells/ml and incubated at 37°C for 3 h under slow continuous 37 
rotation on the MACSmix tube rotator (Miltenyi Biotec). After incubation, the cells were 38 
washed with ice-cold buffer containing 0.5% BSA and 2mM EDTA (Sigma-Aldrich, St. 39 
Louis, MO) in PBS and resuspended at a concentration of 10
8
 cells/ml in ice-cold buffer. The 40 
cells were then stained with detection antibody for 10 min on ice followed by staining of 41 








 cells were sorted using a FACS 42 






















Suppression assay 45 
For T-cell suppression assay, CD4+ T cells were isolated with an AutoMACS (Miltenyi 46 





 ILCs were co-cultured with 48 
carboxy-fluorescein succinimidyl ester (CFSE)-labeled autologous CD4
+
 T cells at different 49 
ratios (total number of cells: 7.5 x 10
4
 cells) in the presence of  1 x 10
5
 irradiated autologous 50 
PBMCs and 2.5 µg/ml of anti-CD3 antibody   in a 96-well 51 




 ILC2 line 52 




 ILCs were 53 
co-cultured with CFSE-labeled autologous ILC2 lines at different ratios (total number of 54 
cells: 7.5 x 10
4
 cells) in the presence of 1 x 10
5
 irradiated autologous PBMCs and 100 U/ml 55 
of recombinant human IL-2 (Proleukin, Novartis, Basel, Switzerland) in a 96-well half-area 56 







Treg cells were sorted with a FACS ARIA II cell sorter after enrichment of CD4+ T cells with 58 
an AutoMACS using a human CD4+ T cell Isolation Kit (Miltenyi Biotec). Treg cells were 59 
co-cultured with CFSE-labeled autologous ILC2 lines at different ratios (total number of 60 
cells: 7.5 x 10
4
 cells) in the presence of  1 x 10
5
 irradiated autologous PBMCs,  2.5 µg/ml of 61 
anti-CD3 antibody  and 100 U/ml of recombinant human 62 
IL-2 (Proleukin) in a 96-well half-area plate (Corning) for 3 days. The average number of cell 63 
divisions were determined as a division index using Flowjo®, and each index was 64 























 To stain IL-10+ ILCs in human nasal tissues, nasal tissue specimens from patients with 68 
CRSwNP and healthy individuals were embedded in optimum cutting temperature (OCT) 69 
compound (Sakura Finetek, Tokyo, Japan) and stored at -80°C until use. 7-µm-thick sections 70 
were placed on glass slides and fixed for 7 min at room temperature in 4% (wt/vol) 71 
paraformaldehyde (PFA) in PBS. After three washes in PBS, the sections were blocked and 72 
made permeable in PBS containing 1% (wt/vol) BSA (Sigma-Aldrich), 10% (vol/vol) 73 
normal human serum (Sigma-Aldrich), 20 mg/ml human IgG (Sigma-Aldrich) and 0.1% 74 
(vol/vol) Triton X-100, followed by use of an Image-iT
TM
 FX signal enhancer (Thermo 75 
Fisher Scientific). For detection of IL-10-producing ILCs, sections were incubated with 76 
mouse anti-! 	
	 "# $	 BD Biosciences), anti-human NCR1 Ab 77 
(MM0491-% Abcam, Cambridge, UK), anti-human IL-10 polyclonal Ab (R&D System, 78 
Minneapolis, MN) or corresponding isotype controls such as mouse IgG1, mouse IgG2b 79 
(Agilent, Santa Clara, CA) and Goat IgG (Jackson ImmunoResearch, West Grove, PA), 80 
followed by incubation with Alexa Fluor 546-conjugated goat anti-mouse IgG1 Ab, Alexa 81 
Fluor 633-conjugated goat anti-mouse IgG2b Ab and Alexa Fluor 488-conjugated donkey 82 
anti-goat IgG Ab (all from Thermo Fisher Scientific). For detection of T cells, the sections 83 
were incubated with Alexa Fluor 647-conjugated rat anti-human CD3 (CD3-12: Bio-Rad, 84 
Hercules, CA). After being stained, sections were mounted with ProLong Gold with DAPI 85 
(Thermo Fisher Scientific) and examined with a Leica TCS SPE confocal microscope (Leica 86 
Microsystems, Heerbrugg, Switzerland). 87 























 mice were embedded in OCT compound (Sakura Finetek) and stored at -80°C until 89 
use. 6-µm-thick sections were placed on glass slides and then fixed in ice-cold acetone and 90 
methanol (1:1) for 1 min. After three washes in PBS, the sections were blocked with 10% 91 
(vol/vol) goat serum (Nichirei, Tokyo, Japan) for 30 min and incubated with rat anti-mouse 92 
sca-1 Ab (D7, BioLegend), hamster anti-mouse CD3 Ab (500A2, BD Biosciences) and 93 
rabbit anti-GFP/venus Ab (Medical & Biological Laboratories, Nagoya, Japan) overnight at 94 
4°C. After three washes in PBS, the sections were incubated with secondary Abs such as 95 
Alexa Fluor 546-conjugated goat anti-rat IgG Ab, Alexa Fluor 647-conjugated goat 96 
anti-hamster IgG Ab and Alexa Fluor 488-conjugated goat anti-rabbit IgG Ab for 1 h at room 97 
temperature. After staining, the sections were mounted with ProLong Diamond Antifade 98 
Mountant with DAPI (Thermo Fisher Scientific) and examined with a confocal microscope 99 
(LSM 510 META ConfoCor, 3, Carl Zeiss, Oberkochen, Germany). 100 
To stain RALDH-1 in mouse lungs, lungs from saline-treated and HDM-treated mice were 101 
fixed with 4% PFA for 24 h and embedded in paraffin. 5-µm-thick sections were 102 
deparaffinized, followed by antigen retrieval (Target Retrieval Solution, Agilent). After three 103 
washes in PBS, the sections were blocked with 1.5 % (wt/vol) horse serum for 20 min and 104 
then incubated with rabbit anti-mouse ALDH1A1 Ab (EP1933Y, Abcam) or isotype Ab 105 
overnight at 4°C. After three washes in PBS, the Envision G/2 System/AP (Agilent) was used 106 
according to the manufacturer’s instructions, followed by counterstaining with hematoxylin. 107 
 108 
RNA isolation and sequencing analysis of RNA-seq data 109 





































 cells using the RNeasy Plus micro Kit (QIAGEN). The quantity 111 
and quality of the isolated RNA were determined with a Qubit® (1.0) Fluorometer (Life 112 
Technologies, CA) and a Bioanalyzer 2100 (Agilent) and samples with an RNA integrity 113 
number of >7.0 were chosen for sequencing. Library preparation for RNA-seq was 114 
performed using the TruSeq Stranded mRNA Sample Prep Kit (Illumina, CA).  115 
Total RNA samples (1 µg) were ribosome-depleted and then reverse-transcribed into 116 
double-stranded cDNA with actinomycin added during first-strand synthesis. The cDNA 117 
samples were fragmented, end-repaired and polyadenylated before ligation with TruSeq 118 
adapters. The adapters contain the index for multiplexing. Fragments containing TruSeq 119 
adapters on both ends were selectively enriched by PCR. The quality and quantity of the 120 
enriched libraries were validated using a Qubit® (1.0) Fluorometer and Bioanalyzer 2100 121 
(Agilent). The product was a smear with an average fragment size of approximately 360 bp. 122 
The libraries were normalized to 10nM in 10 mM Tris-Cl, pH8.5 with 0.1% Tween 20.  123 
A TruSeq SR Cluster Kit v4-cBot-HS or TruSeq PE Cluster Kit v4-cBot-HS (Illumina) was 124 
used for cluster generation using 8 pM of pooled normalized libraries on the cBOT. 125 
Sequencing was performed on an Illumina HiSeq 2500 paired end at 2x126 bp or single end 126 
126 bp using a TruSeq SBS Kit v4-HS (Illumina). Raw data is available at GEO with 127 
accession number: GSE110278. 128 
Sequencing images were transformed with Illumina Basecaller software to bcl files, which 129 
were demultiplexed to FASTQ files with CASAVA v1.8.2 software (Illumina). Quality check 130 
on the reads was performed with FASTQ (v.0.10.0, Babraham Institute, Cambridge, UK). 131 























 implementation of Bowtie software (v 1.0.0)
2
 alignment program with the 133 
Ensembl annotation (v 75). Gene and isoform level abundances were quantified as RPKM 134 
values. "&& &' ( )  !*  + &  ( , - +135 
Foundation for Statistical Computing, Vienna, Austria). Clustering analyses were performed 136 
using the “ward.D2” clustering algorithm implemented in the “hclust” function of R statistics 137 
package. Heatmap plots were prepared with the function “heatmap.2” implemented in the 138 
gplots R package.  139 
Differential expression analysis between two groups was performed using the edgeR 140 
bioconductor package.
3
 Genes present in less than 75% of samples in both conditions were 141 
removed. Q-values were calculated using the Benjamini-Hochberg method and genes with a 142 
q-value <0.05 and an absolute value of log2 (fold change)>1 were kept for further analysis. 143 
Gene ontology (GO) term enrichment analysis was performed using the GOseq bioconductor 144 
package
4
 using the Wallenius approximation. 145 
 146 
Human nasal tissues 147 
Harvesting human nasal tissue from healthy controls and patients with CRS have been 148 
performed according to the Helsinki declarations and Swiss law. The study on nasal mucosal 149 
immunology was approved by the ethical committee of Zurich (KEK ZH 2011-514 and its 150 
amendment in 2012). All subjects included in the study gave written informed consent. 151 
Tissue from control patients was harvested during standard septoplasty procedures from the 152 
inferior turbinate, when performing an anterior turbinoplasty. Polyp tissue was obtained 153 






















Cell isolation from human tissues 156 
Nasal tissues were cut into fine pieces and then digested for 45 min at 37°C in RPMI medium 157 
(Thermo Fisher Scientific) with 2mg/ml collagenase type II (Worthington, Lakewood, NJ) 158 
and 0.04 µg/ml DNase I (Roche, Basel, Switzerland). After incubation, cells were 159 
dissociated using GentleMACS Dissociator (Miltenyi Biotec). Lung tissues were collected 160 
from tumor patients undergoing lobectomy. A small piece of normal lung tissue was cut out 161 
from a part distal from the tumor-affected region. The tissue was minced, washed with PBS 162 
and filtered with a 100-µm filter. Subsequently, tissues were digested for 40 min at 37°C in 163 
RPMI medium (Thermo Fisher Scientific) with 0.25 mg/ml collagenase type II 164 
(Sigma-Aldrich) and 0.2 mg/ml DNase (Roche). After incubation, cold RPMI medium 165 
(0.25ml of 200mM L-glutamine, 1% penicillin/streptomycin) was added to stop the 166 
digestion, and the tissues were mechanically disrupted using a 50-ml syringe and 100-µm 167 
filter. Cell debris and larger alveolar macrophages were separated by density centrifugation 168 
using 30% Percoll (GE Healthcare, Chalfont, UK). 169 
 170 
Cell cultures of human bronchial epithelial cells 171 
Primary bronchial epithelial cells from healthy individuals were expanded as monolayers in 172 
bronchial epithelial cell basal medium supplemented with the SingleQuots Kit (Lonza, Basel, 173 
Switzerland) and then seeded at a density of 150,000 cells in a 6.5-mm diameter polyester 174 
membrane with a pore size of 0.4 µm. Cells were cultured in the medium for ALI culture 175 
described elsewhere
5





















medium in the apical compartment was removed to allow the cells to differentiate. Cells were 177 
used in experiments when the transepithelial electric resistance (TER) reached a plateau. 178 
 179 
 180 
House dust mite (HDM)-induced allergic airway inflammation 181 
Mice were treated intranasally with 20 µl of 1.25 mg/ml HDM extract (Greer Laboratories, 182 
Lenoir, NC) in saline or saline alone, 5 days per week for three consecutive weeks. Three 183 
days after the last intranasal administration, the mice were sacrificed and analyzed. 184 
 185 
Bronchoalveolar lavage fluid (BALF) 186 
Mice were intubated with a 22-G blunt needle (NIPRO, Osaka, Japan) and 1 ml of HBSS 187 
containing 2% FCS was injected through the needle into the lungs. The number of each cell 188 
type was counted with an automated hematology analyzer, Sysmex XT-1800i (Sysmec 189 
Corporation, Hyogo, Japan). ILC2s in the BALFs were analyzed by flow cytometry. 190 
 191 
Isolation of mouse ILC2s from the mesentery 192 
ILC2s were isolated from the mesentery as described described by others.
7
 In brief, mice 193 
underwent transcardial perfusion with PBS to eliminate blood leukocytes, and then the 194 
mesentery was dissected from the intestine. The mesentery was minced with scissors and 195 
incubated at 37°C for 60 min in DMEM containing 4% BSA (Sigma-Aldrich), 20 µg/ml 196 
Liberase DH (Roche) and 1 µg/ml DNase I (Roche). Lin- CD127+ sca-1+ KLRG-1+ ILC2s 197 






















Fig E1. RNA sequencing of IL-10+ and IL-10- ILCs 200 
A, Gating strategy to sort IL-10+ and IL-10- ILCs using an IL-10 secretion assay. B, 201 
Hierarchical clustering of gene expression. C, Flow cytometric analyses of IL-10+ and 202 
ILC2s. D, Gene expression profiles of IL-10+ and IL-10- ILCs.  203 
 204 
Fig E2. Suppression assay 205 
A, Division of CFSE-labeled CD4+ T cells in the presence of IL-10- ILCs at different ratios.  206 
B, Division of CFSE-labeled ILC2s in the presence of IL-10- ILCs at different ratios.  C, 207 
Division of CFSE-labeled ILC2s in the presence of Treg cells at different ratios. The CFSE 208 
fluorescence level was analyzed by flow cytometry, and the division index was calculated. 209 
Data are shown as the mean ± SEM. n = 3 per group, in duplicate. *P<0.05, **P<0.01 210 
between indicated groups. 211 
 212 
Fig E3. Stability of  IL-10+  and IL10-  ILCs 213 
The experimental protocol and the data are shown. Human ILC2 cell lines were stimulated 214 
for 3 days with IL-2, IL-33 and RA, and IL-10+ and IL-10- cells were sorted using an IL-10 215 
secretion assay. The sorted IL-10+ and IL-10- ILCs were then cultured for 3 days in the 216 
presence of IL-2. Subsequently, half of the cells were stimulated for 5 hours with PMA plus 217 
Ionomycin in the presence of Brefeldin A for final 3 hours. The other half of the cells were 218 
restimulated with IL-2, IL-33 and RA for 3days, followed by stimulation with PMA, 219 
Ionomycin and Brefeldin A. The frequencies of IL-10
+





















cytometry (n = 4) 221 
 222 
FIG E4. A fraction of ILC2 clones give rise to IL-10-producing ILCregs in response to 223 
RA. 224 
ILC2 clones were expanded with irradiated PBMCs and recombinant human IL-2 for 3 225 
weeks.  A, ILC2 clones were stimulated with IL-2, or IL-2, IL-33 and all-trans RA, for 3 days. 226 
The frequency of IL-10
+
 ILCs in each ILC2 clones was determined by flow cytometry.  B, 227 
The levels of IL-10 in culture supernatants of ILC2 clones stimulated with IL-2, IL-33 and 228 
all-trans RA were determined by ELISA.  C, The expression levels of c-Kit, CD161, CTLA-4 229 
and IL-13 before all-trans RA stimulation were determined by flow cytometry. Blue dots 230 
(left: n = 25) represent clones that remained IL-10-negative after all-trans RA stimulation. 231 
Red dots (right: n = 10) represent clones that started to produce IL-10 after all-trans RA 232 
stimulation.  D, The levels of IL-5 and IL-13 in culture supernatants of ILC2 clones 233 
stimulated with IL-2, IL-33 and all-trans RA were determined by ELISA. 234 
Blue dots (left: n = 25) represent clones that remained IL-10-negative after all-trans RA 235 
stimulation. Red dots (right: n = 10) represent clones that started to produce IL-10 after 236 
all-trans RA stimulation. Data are shown as the mean ± SEM. NS: not significant between 237 
indicated groups. 238 
 239 
FIG E5. Frequency of IL-10+  immune cells in an HDM-induced asthma-like model 240 
A, Gating strategy for identifying IL-10-producing CD4+ T cells, CD19+ B cells and ILCs in 241 
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